Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016

European Journal of Cancer

Volumn 63, Issue , 2016, Pages 201-217

  Garbe, Claus ^a   Peris, Ketty ^b   Hauschild, Axel ^c   Saiag, Philippe ^d   Middleton, Mark ^e   Bastholt, Lars ^f   Grob, Jean Jacques ^g   Malvehy, Josep ^h   Newton Bishop, Julia ⁱ   Stratigos, Alexander J ^j   Pehamberger, Hubert ^k   Eggermont, Alexander M ^l  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g University Department of Dermatology   (France)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ UNIVERSITY OF LEEDS   (United Kingdom)

^j UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^k Universitatsklinik fur Dermatologie   (Austria)

^l INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Adjuvant treatment; Cutaneous melanoma; Excisional margins; Interferon ; Metastasectomy; Sentinel lymph node dissection; Systemic treatment; Tumour thickness

Indexed keywords

ALPHA INTERFERON; ANTIMETASTATIC AGENT; ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PROGRAMMED DEATH 1 RECEPTOR;

ACRAL MELANOMA; ADJUVANT THERAPY; ALGORITHM; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); CONSENSUS; CUTANEOUS MELANOMA; DISTANT METASTASIS; EPILUMINESCENCE MICROSCOPY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERDISCIPLINARY RESEARCH; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALIGNANT LENTIGO; META ANALYSIS (TOPIC); METASTASIS; METASTATIC MELANOMA; MICROMETASTASIS; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; MUCOSAL MELANOMA; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN METASTASIS; SYSTEMIC THERAPY; TUMOR DIAGNOSIS; TUMOR DIFFERENTIATION; UVEA MELANOMA; ADJUVANT CHEMOTHERAPY; CELL CYCLE CHECKPOINT; CLASSIFICATION; EUROPE; IMMUNOTHERAPY; MELANOMA; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CONSENSUS; DERMOSCOPY; EUROPE; HUMANS; IMMUNOTHERAPY; LYMPH NODE EXCISION; MELANOMA; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84976328992     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.05.005     Document Type: Article

References (158)

1. A.M. Eggermont, A. Spatz, and C. Robert Cutaneous melanoma Lancet 383 9919 2014 816 827
2. C. Garbe, K. Peris, A. Hauschild, P. Saiag, M. Middleton, A. Spatz, and et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline Eur J Cancer 46 2 2010 270 283
3. C. Garbe, A. Hauschild, M. Volkenandt, D. Schadendorf, W. Stolz, U. Reinhold, and et al. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma Melanoma Res 17 6 2007 393 399
4. C. Garbe, A. Hauschild, M. Volkenandt, D. Schadendorf, W. Stolz, U. Reinhold, and et al. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting Melanoma Res 18 2 2008 152 160
5. R. Dummer, M. Guggenheim, A.W. Arnold, R. Braun, and R. von Moos Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma Swiss Med Wkly 141 2011 w13320
6. C. Garbe, A. Hauschild, M. Volkenandt, D. Schadendorf, W. Stolz, U. Reinhold, and et al. Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma Melanoma Res 18 1 2008 61 67
7. J.R. Marsden, J.A. Newton-Bishop, L. Burrows, M. Cook, P.G. Corrie, N.H. Cox, and et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010 Br J Dermatol 163 2 2010 238 256
8. P. Saiag, L. Bosquet, B. Guillot, O. Verola, M.F. Avril, C. Bailly, and et al. Management of adult patients with cutaneous melanoma without distant metastasis. 2005 update of the French standards, options and recommendations guidelines. Summary report Eur J Dermatol 17 4 2007 325 331
9. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent, S. Rosso, J.W. Coebergh, H. Comber, and et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 6 2013 1374 1403
10. U. Leiter, and C. Garbe Epidemiology of melanoma and nonmelanoma skin cancer - the role of sunlight Adv Exp Med Biol 624 2008 89 103
11. C. Garbe, and U. Leiter Melanoma epidemiology and trends Clin Dermatol 27 1 2009 3 9
12. D.C. Whiteman, A.C. Green, and C.M. Olsen The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations to 2031 J Invest Dermatol 2016 10.1016/j.jid.2016.01.035 [Epub ahead of print]
13. J. Bauer, and C. Garbe Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data Pigment Cell Res 16 3 2003 297 306
14. C. Garbe, P. Buttner, J. Weiss, H.P. Soyer, U. Stocker, S. Kruger, and et al. Associated factors in the prevalence of more than 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentigines: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society The J Invest Dermatol 102 5 1994 700 705
15. J.J. Grob, J. Gouvernet, D. Aymar, A. Mostaque, M.H. Romano, A.M. Collet, and et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma Cancer 66 2 1990 387 395
16. E.A. Holly, J.W. Kelly, S.N. Shpall, and S.H. Chiu Number of melanocytic nevi as a major risk factor for malignant melanoma J Am Acad Dermatol 17 3 1987 459 468
17. J.N. Bishop, M. Harland, J. Randerson-Moor, and D.T. Bishop Management of familial melanoma Lancet Oncol 8 1 2007 46 54
18. F.A. de Snoo, M.W. Kroon, W. Bergman, J.A. ter Huurne, J.J. Houwing-Duistermaat, L. van Mourik, and et al. From sporadic atypical nevi to familial melanoma: risk analysis for melanoma in sporadic atypical nevus patients J Am Acad Dermatol 56 5 2007 748 752
19. J.A. Curtin, J. Fridlyand, T. Kageshita, H.N. Patel, K.J. Busam, H. Kutzner, and et al. Distinct sets of genetic alterations in melanoma N Engl J Med 353 20 2005 2135 2147
20. J.A. Curtin, K. Busam, D. Pinkel, and B.C. Bastian Somatic activation of KIT in distinct subtypes of melanoma J Clin Oncol 24 26 2006 4340 4346
21. H. Tsao, M.B. Atkins, and A.J. Sober Management of cutaneous melanoma N Engl J Med 351 10 2004 998 1012
22. W.H. Clark Jr., L. From, E.A. Bernardino, and M.C. Mihm The histogenesis and biologic behavior of primary human malignant melanomas of the skin Cancer Res 29 3 1969 705 727
23. M.C. Mihm Jr., W.H. Clark Jr., and L. From The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas N Engl J Med 284 19 1971 1078 1082
24. V.J. McGovern, M.C. Mihm Jr., C. Bailly, J.C. Booth, W.H. Clark Jr., A.J. Cochran, and et al. The classification of malignant melanoma and its histologic reporting Cancer 32 6 1973 1446 1457
25. A. Viros, J. Fridlyand, J. Bauer, K. Lasithiotakis, C. Garbe, D. Pinkel, and et al. Improving melanoma classification by integrating genetic and morphologic features PLoS Med 5 6 2008 e120
26. D.C. Whiteman, W.J. Pavan, and B.C. Bastian The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin Pigment Cell Melanoma Res 24 5 2011 879 897
27. Cancer Genome Atlas N Genomic classification of cutaneous melanoma Cell 161 7 2015 1681 1696
28. J.L. Maldonado, J. Fridlyand, H. Patel, A.N. Jain, K. Busam, T. Kageshita, and et al. Determinants of BRAF mutations in primary melanomas J Natl Cancer Inst 95 24 2003 1878 1890
29. D. Handolias, R. Salemi, W. Murray, A. Tan, W. Liu, A. Viros, and et al. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure Pigment Cell Melanoma Res 23 2 2010 210 215
30. K. Omholt, E. Grafstrom, L. Kanter-Lewensohn, J. Hansson, and B.K. Ragnarsson-Olding KIT pathway alterations in mucosal melanomas of the vulva and other sites Clin Cancer Res 17 12 2011 3933 3942
31. M.S. Lawrence, P. Stojanov, P. Polak, G.V. Kryukov, K. Cibulskis, A. Sivachenko, and et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes Nature 499 7457 2013 214 218
32. C.M. Balch, J.E. Gershenwald, S.J. Soong, J.F. Thompson, M.B. Atkins, D.R. Byrd, and et al. Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 36 2009 6199 6206
33. J.F. Thompson, S.J. Soong, C.M. Balch, J.E. Gershenwald, S. Ding, D.G. Coit, and et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database J Clin Oncol 29 16 2011 2199 2205
34. A. Spatz, M.G. Cook, D.E. Elder, M. Piepkorn, D.J. Ruiter, and R.L. Barnhill Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas Eur J Cancer 39 13 2003 1861 1865
35. R.A. Scolyer, J.F. Thompson, H.M. Shaw, and S.W. McCarthy The importance of mitotic rate as a prognostic factor for localized primary cutaneous melanoma J Cutan Pathol 33 5 2006 395 396 author reply 7-9
36. A.C. Green, P. Baade, M. Coory, J.F. Aitken, and M. Smithers Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia J Clin Oncol 30 13 2012 1462 1467
37. A. Joosse, S. Collette, S. Suciu, T. Nijsten, F. Lejeune, U.R. Kleeberg, and et al. Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials J Clin Oncol 30 18 2012 2240 2247
38. D.L. Morton, D.R. Wen, J.H. Wong, J.S. Economou, L.A. Cagle, F.K. Storm, and et al. Technical details of intraoperative lymphatic mapping for early stage melanoma Arch Surg 127 4 1992 392 399
39. D.L. Morton, J.F. Thompson, A.J. Cochran, N. Mozzillo, R. Elashoff, R. Essner, and et al. Sentinel-node biopsy or nodal observation in melanoma N Engl J Med 355 13 2006 1307 1317
40. J. Gachon, P. Beaulieu, J.F. Sei, J. Gouvernet, J.P. Claudel, M. Lemaitre, and et al. First prospective study of the recognition process of melanoma in dermatological practice Arch Dermatol 141 4 2005 434 438
41. J.J. Grob, and J.J. Bonerandi The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening Arch Dermatol 134 1 1998 103 104
42. H. Kittler, H. Pehamberger, K. Wolff, and M. Binder Diagnostic accuracy of dermoscopy Lancet Oncol 3 3 2002 159 165
43. S.W. Menzies, C. Ingvar, and W.H. McCarthy A sensitivity and specificity analysis of the surface microscopy features of invasive melanoma Melanoma Res 6 1 1996 55 62
44. F. Nachbar, W. Stolz, T. Merkle, A.B. Cognetta, T. Vogt, M. Landthaler, and et al. The ABCD rule of dermatoscopy. High prospective value in the diagnosis of doubtful melanocytic skin lesions J Am Acad Dermatol 30 4 1994 551 559
45. G. Argenziano, C. Longo, A. Cameron, S. Cavicchini, J.Y. Gourhant, A. Lallas, and et al. Blue-black rule: a simple dermoscopic clue to recognize pigmented nodular melanoma Br J Dermatol 165 6 2011 1251 1255
46. G. Argenziano, H.P. Soyer, S. Chimenti, R. Talamini, R. Corona, F. Sera, and et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet J Am Acad Dermatol 48 5 2003 679 693
47. H. Kittler, P. Guitera, E. Riedl, M. Avramidis, L. Teban, M. Fiebiger, and et al. Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging Arch Dermatol 142 9 2006 1113 1119
48. S.W. Menzies, J. Kreusch, K. Byth, M.A. Pizzichetta, A. Marghoob, R. Braun, and et al. Dermoscopic evaluation of amelanotic and hypomelanotic melanoma Arch Dermatol 144 9 2008 1120 1127
49. F.J. Moloney, and S.W. Menzies Key points in the dermoscopic diagnosis of hypomelanotic melanoma and nodular melanoma J Dermatol 38 1 2011 10 15
50. M.A. Pizzichetta, I. Stanganelli, R. Bono, H.P. Soyer, S. Magi, V. Canzonieri, and et al. Dermoscopic features of difficult melanoma Dermatol Surgery 33 1 2007 91 99
51. W. Stolz, R. Schiffner, and W.H. Burgdorf Dermatoscopy for facial pigmented skin lesions Clin Dermatol 20 3 2002 276 278
52. R. Schiffner, J. Schiffner-Rohe, T. Vogt, M. Landthaler, U. Wlotzke, A.B. Cognetta, and et al. Improvement of early recognition of lentigo maligna using dermatoscopy J Am Acad Dermatol 42 1 Pt 1 2000 25 32
53. P. Pralong, E. Bathelier, S. Dalle, N. Poulalhon, S. Debarbieux, and L. Thomas Dermoscopy of lentigo maligna melanoma: report of 125 cases Br J Dermatol 167 2 2012 280 287
54. H. Koga, and T. Saida Revised 3-step dermoscopic algorithm for the management of acral melanocytic lesions Arch Dermatol 147 6 2011 741 743
55. T. Saida Malignant melanoma in situ on the sole of the foot. Its clinical and histopathologic characteristics Am J Dermatopathol 11 2 1989 124 130
56. T. Saida, S. Oguchi, and A. Miyazaki Dermoscopy for acral pigmented skin lesions Clin Dermatol 20 3 2002 279 285
57. T. Saida, H. Koga, and H. Uhara Key points in dermoscopic differentiation between early acral melanoma and acral nevus J Dermatol 38 1 2011 25 34
58. D. Altamura, E. Altobelli, T. Micantonio, D. Piccolo, M.C. Fargnoli, and K. Peris Dermoscopic patterns of acral melanocytic nevi and melanomas in a white population in central Italy Arch Dermatol 142 9 2006 1123 1128
59. H. Kittler, and M. Binder Follow-up of melanocytic skin lesions with digital dermoscopy: risks and benefits Arch Dermatol 138 10 2002 1379
60. J. Bauer, A. Blum, U. Strohhacker, and C. Garbe Surveillance of patients at high risk for cutaneous malignant melanoma using digital dermoscopy Br J Dermatol 152 1 2005 87 92
61. H.A. Haenssle, U. Krueger, C. Vente, K.M. Thoms, H.P. Bertsch, M. Zutt, and et al. Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma J Invest Dermatol 126 5 2006 980 985
62. I. Alarcon, C. Carrera, J. Palou, L. Alos, J. Malvehy, and S. Puig Impact of in vivo reflectance confocal microscopy on the number needed to treat melanoma in doubtful lesions Br J Dermatol 170 4 2014 802 808
63. D.J. Ruiter, A. Spatz, J.J. van den Oord, and M.G. Cook Pathologic staging of melanoma Semin Oncol 29 4 2002 370 381
64. C. Garbe, T.K. Eigentler, U. Keilholz, A. Hauschild, and J.M. Kirkwood Systematic review of medical treatment in melanoma: current status and future prospects Oncologist 16 1 2011 5 24
65. M. Colombino, M. Capone, A. Lissia, A. Cossu, C. Rubino, V. De Giorgi, and et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma J Clin Oncol 30 20 2012 2522 2529
66. R.D. Carvajal, C.R. Antonescu, J.D. Wolchok, P.B. Chapman, R.A. Roman, J. Teitcher, and et al. KIT as a therapeutic target in metastatic melanoma JAMA 305 22 2011 2327 2334
67. J. Guo, L. Si, Y. Kong, K.T. Flaherty, X. Xu, Y. Zhu, and et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification J clin Oncol 29 21 2011 2904 2909
68. A. Hauschild, F. Rosien, and S. Lischner Surgical standards in the primary care of melanoma patients Onkologie 26 3 2003 218 222
69. R.C. Martin 2nd, C.R. Scoggins, M.I. Ross, D.S. Reintgen, R.D. Noyes, M.J. Edwards, and et al. Is incisional biopsy of melanoma harmful? Am J Surg 190 6 2005 913 917
70. A. Pflugfelder, B. Weide, T.K. Eigentler, A. Forschner, U. Leiter, L. Held, and et al. Incisional biopsy and melanoma prognosis: facts and controversies Clin Dermatol 28 3 2010 316 318
71. D.G. Coit, R. Andtbacka, C.K. Bichakjian, R.A. Dilawari, D. Dimaio, V. Guild, and et al. Melanoma J Natl Compr Cancer Netw 7 3 2009 250 275
72. SaNZGGW TcCAaACN Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical practice guidelines for the management of melanoma in Australia and New Zealand 2008
73. S. Negrier, P. Saiag, B. Guillot, O. Verola, M.F. Avril, C. Bailly, and et al. Guidelines for clinical practice: standards, options and recommendations 2005 for the management of adult patients exhibiting an M0 cutaneous melanoma, full report. National Federation of Cancer Campaign Centers. French Dermatology Society. Update of the 1995 Consensus Conference and the 1998 Standards, Options, and Recommendations Annal Dermatol Venereol 132 12 Pt 2 2005 10S3-S85
74. K. Wheatley, J.S. Wilson, P. Gaunt, and J.R. Marsden Surgical excision margins in primary cutaneous melanoma: a meta-analysis and Bayesian probability evaluation Cancer Treat Rev 42 2016 73 81
75. A.J. Hayes, L. Maynard, G. Coombes, J. Newton-Bishop, M. Timmons, M. Cook, and et al. Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial Lancet Oncol 17 2 2016 184 192
76. M. Moehrle, K. Dietz, C. Garbe, and H. Breuninger Conventional histology vs. three-dimensional histology in lentigo maligna melanoma Br J Dermatol 154 3 2006 453 459
77. U.V. Buettiker, N.Y. Yawalkar, L.R. Braathen, and R.E. Hunger Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients Arch Dermatol 144 7 2008 943 945
78. M.H. Mahoney, M.G. Joseph, and C. Temple Topical imiquimod therapy for lentigo maligna Ann Plast Surg 61 4 2008 419 424
79. M.A. Cotter, J.K. McKenna, and G.M. Bowen Treatment of lentigo maligna with imiquimod before staged excision Dermatol Surg 34 2 2008 147 151
80. M. Moehrle, S. Metzger, W. Schippert, C. Garbe, G. Rassner, and H. Breuninger "Functional" surgery in subungual melanoma Dermatol Surg 29 4 2003 366 374
81. H. Breuninger, B. Schlagenhauff, W. Stroebel, G. Schaumburg-Lever, and G. Rassner Patterns of local horizontal spread of melanomas: consequences for surgery and histopathologic investigation Am J Surg Pathol 23 12 1999 1493 1498
82. C.L. Temple, and J.P. Arlette Mohs micrographic surgery in the treatment of lentigo maligna and melanoma J Surg Oncol 94 4 2006 287 292
83. D.L. Morton, L. Wanek, J.A. Nizze, R.M. Elashoff, and J.H. Wong Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic Ann Surg 214 4 1991 491 499 discussion 9-501
84. J.F. Thompson, and H.M. Shaw Sentinel node mapping for melanoma: results of trials and current applications Surg Oncol Clin N Am 16 1 2007 35 54
85. D.L. Morton, A.J. Cochran, J.F. Thompson, R. Elashoff, R. Essner, E.C. Glass, and et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial Ann Surg 242 3 2005 302 311 discussion 11-3
86. U. Leiter, R. Stadler, C. Mauch, W. Hohenberger, N. Brockmeyer, C. Berking, and et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial Lancet Oncol 17 6 2016 757 767
87. A.P. van der Ploeg, A.C. van Akkooi, P. Rutkowski, M. Cook, O.E. Nieweg, C.R. Rossi, and et al. Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection Br J Surg 99 10 2012 1396 1405
88. D. Lienard, A.M. Eggermont, H.S. Koops, B. Kroon, G. Towse, S. Hiemstra, and et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study Melanoma Res 9 5 1999 491 502
89. J.P. Deroose, A.M. Eggermont, A.N. van Geel, J.H. de Wilt, J.W. Burger, and C. Verhoef 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters Ann Surg Oncol 19 2 2012 627 635
90. R.H. Andtbacka, H.L. Kaufman, F. Collichio, T. Amatruda, N. Senzer, J. Chesney, and et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma J Clin Oncol 33 25 2015 2780 2788
91. B. Weide, M. Elsasser, P. Buttner, A. Pflugfelder, U. Leiter, T.K. Eigentler, and et al. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis Br J Cancer 107 3 2012 422 428
92. R.P. Petersen, S.I. Hanish, J.C. Haney, C.C. Miller 3rd, W.R. Burfeind Jr., D.S. Tyler, and et al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma J Thorac Cardiovasc Surg 133 1 2007 104 110
93. A. Sanki, R.A. Scolyer, and J.F. Thompson Surgery for melanoma metastases of the gastrointestinal tract: indications and results Eur J Surg Oncol 35 3 2009 313 319
94. T.C. Chua, A. Saxena, and D.L. Morris Surgical metastasectomy in AJCC stage IV M1c melanoma patients with gastrointestinal and liver metastases Ann Acad Med Singapore 39 8 2010 634 639
95. N. Wasif, S.P. Bagaria, P. Ray, and D.L. Morton Does metastasectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes J Surg Oncol 104 2 2011 111 115
96. S.J. Moschos, H.D. Edington, S.R. Land, U.N. Rao, D. Jukic, J. Shipe-Spotloe, and et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses J Clin Oncol 24 19 2006 3164 3171
97. B.H. Burmeister, M.A. Henderson, J. Ainslie, R. Fisher, J. Di Iulio, B.M. Smithers, and et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial Lancet Oncol 13 6 2012 589 597
98. K.R. Olivier, S.E. Schild, C.G. Morris, P.D. Brown, and S.N. Markovic A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma Cancer 110 8 2007 1791 1795
99. W.R. Rate, L.J. Solin, and A.T. Turrisi Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression Int J Radiat Oncol Biol Phys 15 4 1988 859 864
100. H.R. Katz The results of different fractionation schemes in the palliative irradiation of metastatic melanoma Int J Radiat Oncol Biol Phys 7 7 1981 907 911
101. J.B. Konefal, B. Emami, and M.V. Pilepich Analysis of dose fractionation in the palliation of metastases from malignant melanoma Cancer 61 2 1988 243 246
102. Y.M. Kirova, J. Chen, L.I. Rabarijaona, Y. Piedbois, and J.P. Le Bourgeois Radiotherapy as palliative treatment for metastatic melanoma Melanoma Res 9 6 1999 611 613
103. D.W. Andrews, C.B. Scott, P.W. Sperduto, A.E. Flanders, L.E. Gaspar, M.C. Schell, and et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial Lancet 363 9422 2004 1665 1672
104. R.A. Patchell, P.A. Tibbs, W.F. Regine, R.J. Dempsey, M. Mohiuddin, R.J. Kryscio, and et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial JAMA 280 17 1998 1485 1489
105. N. Kased, K. Huang, J.L. Nakamura, A. Sahgal, D.A. Larson, M.W. McDermott, and et al. Gamma knife radiosurgery for brainstem metastases: the UCSF experience J Neurooncol 86 2 2008 195 205
106. H.S. Koops, M. Vaglini, S. Suciu, B.B. Kroon, J.F. Thompson, J. Gohl, and et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593 J Clin Oncol 16 9 1998 2906 2912
107. H. Pehamberger, H.P. Soyer, A. Steiner, R. Kofler, M. Binder, P. Mischer, and et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group J Clin Oncol 16 4 1998 1425 1429
108. C. Garbe, P. Radny, R. Linse, R. Dummer, R. Gutzmer, J. Ulrich, and et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis Ann Oncol 19 6 2008 1195 1201
109. U.R. Kleeberg, S. Suciu, E.B. Brocker, D.J. Ruiter, C. Chartier, D. Lienard, and et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis Eur J Cancer 40 3 2004 390 402
110. B.W. Hancock, K. Wheatley, S. Harris, N. Ives, G. Harrison, J.M. Horsman, and et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma J Clin Oncol 22 1 2004 53 61
111. N. Cascinelli, F. Belli, R.M. MacKie, M. Santinami, R. Bufalino, and A. Morabito Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial Lancet 358 9285 2001 866 869
112. D.A. Cameron, M.C. Cornbleet, R.M. Mackie, J.A. Hunter, M. Gore, B. Hancock, and et al. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study Br J Cancer 84 9 2001 1146 1149
113. J.M. Kirkwood, J.G. Ibrahim, V.K. Sondak, J. Richards, L.E. Flaherty, M.S. Ernstoff, and et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 J Clin Oncol 18 12 2000 2444 2458
114. J.J. Grob, B. Dreno, P. de la Salmoniere, M. Delaunay, D. Cupissol, B. Guillot, and et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma Lancet 351 9120 1998 1905 1910
115. J. Hansson, S. Aamdal, L. Bastholt, Y. Brandberg, M. Hernberg, B. Nilsson, and et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial Lancet Oncol 12 2 2011 144 152
116. A.M. Eggermont, S. Suciu, R. MacKie, W. Ruka, A. Testori, W. Kruit, and et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial Lancet 366 9492 2005 1189 1196
117. J.M. Kirkwood, M.H. Strawderman, M.S. Ernstoff, T.J. Smith, E.C. Borden, and R.H. Blum Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 1 1996 7 17
118. E.T. Creagan, R.J. Dalton, D.L. Ahmann, S.H. Jung, R.F. Morton, R.M. Langdon Jr., and et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma J Clin Oncol 13 11 1995 2776 2783
119. A.M. Eggermont, S. Suciu, M. Santinami, A. Testori, W.H. Kruit, J. Marsden, and et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Lancet 372 9633 2008 117 126
120. S. Mocellin, S. Pasquali, C.R. Rossi, and D. Nitti Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis J Natl Cancer Inst 102 7 2010 493 501
121. A.M. Eggermont, S. Suciu, A. Testori, W.H. Kruit, J. Marsden, C.J. Punt, and et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991 Eur J Cancer 48 2 2012 218 225
122. A.M. Eggermont, S. Suciu, A. Testori, M. Santinami, W.H. Kruit, J. Marsden, and et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma J Clin Oncol 30 31 2012 3810 3818
123. A.M. Eggermont, S. Suciu, P. Rutkowski, W.H. Kruit, C.J. Punt, R. Dummer, and et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity Eur J Cancer 55 2016 111 121
124. S. Suciu, N. Ives, A.M. Eggermont, and et al. Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): an individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts) J Clin Oncol 32 5s 2014 abstract 9067
125. A.M. Eggermont, V. Chiarion-Sileni, J.J. Grob, R. Dummer, J.D. Wolchok, H. Schmidt, and et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial Lancet Oncol 16 5 2015 522 530
126. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, and et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 26 2011 2507 2516
127. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 8 2010 711 723
128. J.M. Ko, and D.E. Fisher A new era: melanoma genetics and therapeutics J Pathol 223 2 2011 241 250
129. J.A. Sosman, K.B. Kim, L. Schuchter, R. Gonzalez, A.C. Pavlick, J.S. Weber, and et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 8 2012 707 714
130. C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski, A. Mackiewicz, D. Stroiakovski, and et al. Improved overall survival in melanoma with combined dabrafenib and trametinib N Engl J Med 372 1 2015 30 39
131. J. Larkin, P.A. Ascierto, B. Dreno, V. Atkinson, G. Liszkay, M. Maio, and et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma N Engl J Med 371 20 2014 1867 1876
132. R. Dummer, P. Arenberger, P.A. Ascierto, J.W. De Groot, S. Hallmeyer, M. Lotem, and et al. 1130TiP-NEMO: a phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with advanced NRAS-mutant melanoma who are untreated or have progressed after any number of immunotherapy regimens Ann Oncol 25 Suppl. 4 2014 iv392
133. Y. Zhao, and A.A. Adjei The clinical development of MEK inhibitors Nat Rev Clin Oncol 11 7 2014 385 400
134. D.L. Morton, N. Mozzillo, J.F. Thompson, and et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites 25 ed 2007 8508
135. J.G. Greger, S.D. Eastman, V. Zhang, M.R. Bleam, A.M. Hughes, K.N. Smitheman, and et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations Mol Cancer Ttherapeutics 11 4 2012 909 920
136. G.S. Falchook, G.V. Long, R. Kurzrock, K.B. Kim, T.H. Arkenau, M.P. Brown, and et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Lancet 379 9829 2012 1893 1901
137. G.V. Long, U. Trefzer, M.A. Davies, R.F. Kefford, P.A. Ascierto, P.B. Chapman, and et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial Lancet Oncol 13 11 2012 1087 1095
138. C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, and et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 26 2011 2517 2526
139. C. Robert, G.V. Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier, and et al. Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 4 2015 320 330
140. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454
141. C. Robert, J. Schachter, G.V. Long, A. Arance, J.J. Grob, L. Mortier, and et al. Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 372 26 2015 2521 2532
142. J. Larkin, F.S. Hodi, and J.D. Wolchok Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 13 2015 1270 1271
143. A.Y. Bedikian, R.C. DeConti, R. Conry, S. Agarwala, N. Papadopoulos, K.B. Kim, and et al. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma Ann Oncol 22 4 2011 787 793
144. P.M. Patel, S. Suciu, L. Mortier, W.H. Kruit, C. Robert, D. Schadendorf, and et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032) Eur J Cancer 47 10 2011 1476 1483
145. A.Y. Bedikian, M. Millward, H. Pehamberger, R. Conry, M. Gore, U. Trefzer, and et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group J Clin Oncol 24 29 2006 4738 4745
146. M.R. Middleton, J.J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, and et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 1 2000 158 166
147. U. Ringborg, C.M. Rudenstam, J. Hansson, L. Hafstrom, B. Stenstam, and H. Strander Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study Med Oncol Tumor Pharmacother 6 4 1989 285 289
148. V. Chiarion Sileni, R. Nortilli, S.M. Aversa, A. Paccagnella, M. Medici, L. Corti, and et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients Melanoma Res 11 2 2001 189 196
149. A.M. Young, J. Marsden, A. Goodman, A. Burton, and J.A. Dunn Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma Clin Oncol (R Coll Radiol) 13 6 2001 458 465
150. N.M. Bleehen, E.S. Newlands, S.M. Lee, N. Thatcher, P. Selby, A.H. Calvert, and et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma J Clin Oncol 13 4 1995 Apr 910 913
151. C. Jacquillat, D. Khayat, P. Banzet, M. Weil, M.F. Avril, P. Fumoleau, and et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma Cancer Chemother Pharmacol 25 4 1990 263 266
152. F. Mornex, L. Thomas, P. Mohr, A. Hauschild, M.M. Delaunay, T. Lesimple, and et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma Melanoma Res 13 1 2003 97 103
153. R.D. Rao, S.G. Holtan, J.N. Ingle, G.A. Croghan, L.A. Kottschade, E.T. Creagan, and et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma Cancer 106 2 2006 Jan 15 375 382
154. C.F. Verschraegen, U.R. Kleeberg, J. Mulder, P. Rumke, F. Truchetet, B. Czarnetzki, and et al. Combination of cisplatin, vindesine and dacarbazine in advanced malignant melanoma Cancer 62 1988 1061 1065
155. S. Leyvraz, V. Spataro, J. Bauer, S. Pampallona, R. Salmon, T. Dorval, and et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy J Clin Oncol 15 7 1997 Jul 2589 2595
156. G. Egerer, T. Lehnert, R. Max, H. Naeher, U. Keilholz, and A.D. Ho Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients Int J Clin Oncol 6 1 2001 25 28
157. R. Siegel, A. Hauschild, C. Kettelhack, K.C. Kahler, A. Bembenek, and P.M. Schlag Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma Eur J Surg Oncol 33 5 2007 627 632
158. C. Pföhler, I.A. Cree, S. Ugurel, C. Kuwert, N. Haass, K. Neuber, and et al. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study Anticancer Drugs 14 5 2003 Jun 337 340